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background:  Evolocumab (AMG 145), a fully human monoclonal antibody inhibiting PCSK9, significantly reduced LDL-C in phase 2 and 
3 studies. This phase 3 study (the largest PCSK9 inhibitor study in Japan to date) examined the efficacy and safety of evolocumab in high 
CV risk Japanese patients on stable statin therapy.
Methods:  Patients aged 20-80 years were initially randomized to atorvastatin 5 or 20 mg daily. After a 4-week stabilization period, patients 
underwent a second randomization to SC placebo or evolocumab 140 mg every two weeks (Q2W) or 420 mg every month (QM). Co-
primary endpoints were percent reduction from baseline in LDL-C at week 12 and at the mean of weeks 10 and 12 (which better reflects 
average LDL-C reduction). Secondary endpoints included assessments of other lipids and the proportion of patients reaching LDL-C <70 
mg/dL. Adverse events and laboratory values were recorded.
Results:  404 patients were randomized to and dosed with investigational product; 23% of the patients had coronary, cerebrovascular or 
peripheral arterial disease, 49% were diabetic, and 74% had hypertension. The mean (SD) age was 61 (10) years, 40% were female, and 
mean (SD) calculated LDL-C was 128 (23) mg/dL upon study entry. In patients receiving evolocumab, mean reductions in LDL-C ranged 
from approximately 65-77% (Table), with 96-98% of patients achieving LDL-C <70 mg/dL.
conclusion:  In high-risk Japanese patients receiving stable statin therapy, evolocumab significantly reduced LDL-C and was well 
tolerated. 
